Compugen Ltd. (NASDAQ:CGEN) Receives $5.00 Consensus Target Price from Brokerages

Compugen Ltd. (NASDAQ:CGEN) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $5.00.

A number of research firms have recently issued reports on CGEN. Truist Financial raised shares of Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen cut shares of Compugen from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Leerink Partners lowered their price target on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, May 21st. Lake Street Capital initiated coverage on shares of Compugen in a research report on Tuesday, April 7th. They set a “buy” rating and a $6.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th.

Hedge Funds Weigh In On Compugen

Several institutional investors and hedge funds have recently bought and sold shares of CGEN. Platform Technology Partners increased its stake in Compugen by 10.0% in the 1st quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 5,000 shares during the period. State Street Corp boosted its stake in shares of Compugen by 3.9% during the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after purchasing an additional 14,701 shares during the period. Two Sigma Investments LP grew its holdings in shares of Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 18,929 shares during the last quarter. Glenmede Trust Co. NA grew its holdings in shares of Compugen by 187.5% in the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 22,500 shares during the last quarter. Finally, Bank Hapoalim BM purchased a new position in shares of Compugen in the fourth quarter worth $37,000. 12.22% of the stock is currently owned by institutional investors.

Compugen Trading Down 1.3%

Compugen stock opened at $2.33 on Friday. The firm has a 50 day simple moving average of $2.37 and a 200 day simple moving average of $2.21. Compugen has a 1-year low of $1.29 and a 1-year high of $3.23. The firm has a market capitalization of $220.30 million, a price-to-earnings ratio of 6.30 and a beta of 2.76.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, May 18th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The company had revenue of $2.18 million during the quarter, compared to the consensus estimate of $1.57 million. Compugen had a return on equity of 47.72% and a net margin of 47.97%. On average, equities research analysts forecast that Compugen will post -0.28 EPS for the current year.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.